1. Home
  2. MIRM vs TGL Comparison

MIRM vs TGL Comparison

Compare MIRM & TGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$78.49

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

TGL

Treasure Global Inc.

HOLD

Current Price

$7.23

Market Cap

10.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
TGL
Founded
2018
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
10.7M
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
MIRM
TGL
Price
$78.49
$7.23
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
$92.45
N/A
AVG Volume (30 Days)
790.7K
2.4M
Earning Date
11-04-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$471,794,000.00
$2,305,713.00
Revenue This Year
$53.78
N/A
Revenue Next Year
$19.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
53.66
N/A
52 Week Low
$36.88
$4.51
52 Week High
$79.95
$780.00

Technical Indicators

Market Signals
Indicator
MIRM
TGL
Relative Strength Index (RSI) 69.86 52.91
Support Level $63.23 $4.51
Resistance Level $66.77 $8.78
Average True Range (ATR) 3.33 6.91
MACD 0.90 -0.44
Stochastic Oscillator 98.15 11.99

Price Performance

Historical Comparison
MIRM
TGL

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About TGL Treasure Global Inc.

Treasure Global Inc. has created an online-to-offline e-commerce platform business model that offers consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retail or merchant settings. Its product is an internet application branded as the ZCITY app, which targets consumers by providing personalized deals based on their purchase history, location, and preferences. The Company has two reportable segments: (i) payment processing and e-commerce operation in its ZCITY platform, and (ii) customized software development service, and the majority of revenue comes from payment processing and e-commerce operation in its ZCITY platform.

Share on Social Networks: